An introduction to EpiAxis Therapeutics
EpiAxis Therapeutics is a privately funded, leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer, and the prevention of its recurrence.
Our lead therapeutic candidate (EPI-111) targets the eraser enzyme lysine-specific demethylase 1 (LSD1) and has a dual mechanism to treat cancer by:
1) targeting the dormant cancer cells that seed cancer recurrence and, concurrently
Importantly we have demonstrated clinical proof of concept in reprogramming cancer cells by targeting LSD1 in our pioneering EPI-PRIMED clinical trial. In addition to first-in-class assets we have dominant intellectual property covering targeting of LSD1 in combination with surgery, other drugs including radiotherapy
across the metastatic setting. We also have projects targeting PKC theta and PD1/PDL1.
EpiAxis was established in 2015 from research conducted by its Founding Scientist – Professor Sudha Rao (above), a leading epigenetic researcher. The company won the BioPharma Best Pitch in 2016, was also runner-up for Most Investable Company and won the BioEurope Startup Slam in the same year. Prof Rao was initially based at the University of Canberra and is now with the QIMR Berghofer Medical Research Institute.